Association of high-density lipoprotein with development of metabolic syndrome components: A five-year follow-up in adults

BMC Public Health

Volumn 15, Issue 1, 2015, Pages

  Liu, Xiangtong ^a   Tao, Lixin ^a   Cao, Kai ^a   Wang, Zhaoping ^b   Chen, Dongning ^b   Guo, Jin ^a   Zhu, Huiping ^a   Yang, Xinghua ^a   Wang, Youxin ^a   Wang, Jingjing ^a   Wang, Chao ^a   Liu, Long ^a   Guo, Xiuhua ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Adults; Follow up study; High density lipoprotein; Metabolic syndrome

Indexed keywords

GLUCOSE BLOOD LEVEL; HIGH DENSITY LIPOPROTEIN;

ADULT; AGED; BLOOD; BLOOD PRESSURE; CHINA; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; INCIDENCE; MALE; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

ADULT; AGED; BEIJING; BLOOD GLUCOSE; BLOOD PRESSURE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LIPOPROTEINS, HDL; MALE; METABOLIC SYNDROME X; MIDDLE AGED;

EID: 84928398291     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/s12889-015-1747-9     Document Type: Article

References (35)

1. Samson SL, Garber AJ. Metabolic syndrome. Endocrinol Metab Clin N Am. 2014;43(1):1-23.
2. Del Brutto OH, Zambrano M, Penaherrera E, Montalvan M, Pow-Chon-Long F, Tettamanti D. Prevalence of the metabolic syndrome and its correlation with the cardiovascular health status in stroke- and ischemic heart disease-free Ecuadorian natives/mestizos aged >/=40 years living in Atahualpa: a population-based study. Diabetes & Metabolic Syndrome. 2013;7(4):218-22.
3. Sheikhbahaei S, Fotouhi A, Hafezi-Nejad N, Nakhjavani M, Esteghamati A. Serum uric acid, the metabolic syndrome, and the risk of chronic kidney disease in patients with type 2 diabetes. Metab Syndr Relat Disord. 2014;12(2):102-9.
4. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007;49(4):403-14.
5. Wang F, Ye P, Hu D, Min Y, Zhao S, Wang Y, et al. Lipid-lowering therapy and lipid goal attainment in patients with metabolic syndrome in China: Subgroup analysis of the Dyslipidemia International Study-China (DYSIS-China). Atherosclerosis. 2014;237(1):99-105.
6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-97.
7. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735-52.
8. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-421.
9. Rader DJ, Hovingh GK. HDL and cardiovascular disease. Lancet. 2014;384(9943):618-25.
10. Moriyama K, Negami M, Takahashi E. HDL2-cholesterol/HDL3-cholesterol ratio was associated with insulin resistance, high-molecular-weight adiponectin, and components for metabolic syndrome in Japanese. Diabetes Res Clin Pract. 2014;106(2):360-5.
11. Franco OH, Massaro JM, Civil J, Cobain MR, O'Malley B, D'Agostino Sr RB. Trajectories of entering the metabolic syndrome: the framingham heart study. Circulation. 2009;120(20):1943-50.
12. Scuteri A, Morrell CH, Najjar SS, Muller D, Andres R, Ferrucci L, et al. Longitudinal paths to the metabolic syndrome: can the incidence of the metabolic syndrome be predicted? The Baltimore Longitudinal Study of Aging. J Gerontol A: Biol Med Sci. 2009;64(5):590-8.
13. Haring R, Rosvall M, Volker U, Volzke H, Kroemer H, Nauck M, et al. A network-based approach to visualize prevalence and progression of metabolic syndrome components. PLoS One. 2012;7(6):e39461.
14. Huo D, Tao L, Li X, Wang W, Wang Z, Chen D, et al. Association of blood pressure with development of metabolic syndrome components: a five-year Retrospective Cohort study in Beijing. BMC Public Health. 2013;13:912.
15. Tan P-N KV, Srivastava J. Selecting the right objective measure for association analysis. Inf Syst. 2004;29(4):293-313.
16. Tao LX, Li X, Zhu HP, Huo D, Zhou T, Pan L, et al. Association of hematological parameters with metabolic syndrome in Beijing adult population: a longitudinal study. Endocrine. 2014;46(3):485-95.
17. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-5.
18. Gierach M, Gierach J, Ewertowska M, Arndt A, Junik R. Correlation between body mass index and waist circumference in patients with metabolic syndrome. ISRN Endocrinology. 2014;2014:514589.
19. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157-63.
20. Park SH, Jang SY, Kim H, Lee SW. An association rule mining-based framework for understanding lifestyle risk behaviors. PLoS One. 2014;9(2), e88859.
21. Stilou S, Bamidis PD, Maglaveras N, Pappas C. Mining association rules from clinical databases: an intelligent diagnostic process in healthcare. Stud Health Tech Informat. 2001;84(Pt 2):1399-403.
22. Ma L, Tsui FC, Hogan WR, Wagner MM, Ma H. A framework for infection control surveillance using association rules. AMIA Annu Symp Proc. 2003:410-4. http://www.ncbi.nlm.nih.gov/pubmed/?term=A+framework+for+infection+489+control+surveillance+using+association+rules.
23. Yadav D, Mishra M, Tiwari A, Bisen PS, Goswamy HM, Prasad GB. Prevalence of dyslipidemia and hypertension in Indian type 2 diabetic patients with metabolic syndrome and its clinical significance. Osong Public Health Res Perspect. 2014;5(3):169-75.
24. Ferguson TF, Funkhouser E, Roseman J. Factor analysis of metabolic syndrome components in the Coronary Artery Risk Development in Young Adults (CARDIA) study: examination of factors by race-sex groups and across time. Ann Epidemiol. 2010;20(3):194-200.
25. Shen BJ, Goldberg RB, Llabre MM, Schneiderman N. Is the factor structure of the metabolic syndrome comparable between men and women and across three ethnic groups: the Miami Community Health Study. Ann Epidemiol. 2006;16(2):131-7.
26. Shen BJ, Todaro JF, Niaura R, McCaffery JM, Zhang J, Spiro 3rd A, et al. Are metabolic risk factors one unified syndrome? Modeling the structure of the metabolic syndrome X. Am J Epidemiol. 2003;157(8):701-11.
27. Guyton JR, Slee AE, Anderson T, Fleg JL, Goldberg RB, Kashyap ML, et al. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). J Am Coll Cardiol. 2013;62(17):1580-4.
28. Tao LX, Wang W, Zhu HP, Huo D, Zhou T, Pan L, et al. Risk profiles for metabolic syndrome and its transition patterns for the elderly in Beijing, 1992-2009. Endocrine. 2014;47(1):161-8.
29. Onat A. Metabolic syndrome: nature, therapeutic solutions and options. Expert Opin Pharmacother. 2011;12(12):1887-900.
30. Onat A, Can G, Murat S, Cicek G, Ornek E, Yuksel H. Aggregation of lipoprotein(a) to apolipoprotein A-I underlying HDL dysfunction as a major coronary risk factor. Anadolu Kardiyol Derg. 2013;13(6):543-51.
31. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among u.s. Adults. Diabetes Care. 2004;27(10):2444-9.
32. Klop B, Elte JW, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients. 2013;5(4):1218-40.
33. Onat A, Can G. Enhanced proinflammatory state and autoimmune activation: a breakthrough to understanding chronic diseases. Curr Pharm Des. 2014;20(4):575-84.
34. Li JH, Wang LM, Mi SQ, Zhang M, Li YC, Jiang Y, et al. [Awareness rate, treatment rate and control rate of dyslipidemia in Chinese adults. Zhonghua yu fang yi xue za zhi. 2010;46(8):687-91.
35. Freiberg MS, Pencina MJ, D'Agostino RB, Lanier K, Wilson PW, Vasan RS. BMI vs waist circumference for identifying vascular risk. Obesity. 2008;16(2):463-9.